Clinical Trial Detail

NCT ID NCT01218867
Title Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors National Cancer Institute (NCI)
Indications

colorectal cancer

kidney cancer

ovarian cancer

lung cancer

Advanced Solid Tumor

melanoma

Therapies

Anti-VEGFR2 CAR CD8 lymphocytes

Cyclophosphamide

Fludarabine

Aldesleukin

Age Groups: adult senior

No variant requirements are available.